Efgartigimod IV for Seronegative Generalized Myasthenia Gravis

Efgartigimod IV for Seronegative Generalized Myasthenia Gravis
72%49%27%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 26 • YES 58.0%Apr 27 • YES 34.0%Apr 28 • YES 34.0%Apr 29 • YES 34.0%Apr 30 • YES 34.0%May 1 • YES 34.0%May 2 • YES 34.0%May 3 • YES 34.0%May 4 • YES 34.0%May 5 • YES 34.0%May 7 • YES 60.1%May 12 • YES 60.1%May 13 • YES 64.7%
argenx ($ARGX)
No stock closeNo stock close$819.4$794.2$768.9Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 27 • ARGX $783.7Apr 28 • ARGX $775.0Apr 29 • ARGX $776.0Apr 30 • ARGX $781.7May 1 • ARGX $783.5May 4 • ARGX $811.1May 5 • ARGX $794.7May 6 • ARGX $807.6May 7 • ARGX $787.3May 8 • ARGX $782.2May 11 • ARGX $813.3

Will this trial show a positive result on MG-ADL total score change from baseline?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Primary Completion
6/30/25
Study Completion
6/1/27
Sponsor
argenx
Ticker
$ARGX
Type
Phase 3
Trial Status
Active, not recruiting
Trial Size
119
NCT
NCT06298552
Trial Description
Efgartigimod IV is tested in adults with AChR antibody-seronegative generalized myasthenia gravis, measuring change in daily-activity symptom score after 29 days.